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Antimalarial drugs have long been used to
treat acute cases of malaria, to cure infec-
tion, and to prevent disease progression,
severe disease, and death. They have also
been used to prevent illness (e.g., che-
moprophylaxis) and to reduce transmis-
sion (e.g., mass drug administration cou-
pled with vector control measures). With
each preventive strategy, the balance of ef-
ficacy and long-term feasibility has led to
progressively more focused use of the
drug. That is, mass drug administration
and broad use of chemoprophylaxis in a
population have been reduced to targeted
drug administration to fewer people and
only specific groups or to shorter time in-
tervals, to maximize benefits and to reduce
costs, poor adherence, and the potential
impact on drug resistance.
Among pregnant women in settings
where malaria is endemic, who have long
been a target population for chemopro-
phylaxis, studies have demonstrated that
a few treatment doses of a safe and effi-
cacious antimalarial at intervals linked to
routine antenatal clinic visits could pro-
duce a substantial reduction in rates of
maternal anemia, placental parasite infec-
tion, and the attendant risk of low birth
weight. This proactive and presumptive
(not linked to symptoms or documenta-
tion of infection) use of treatment doses
at a few specific intervals, which is known
as “intermittent preventive treatment
(IPT) during pregnancy,” has been widely
adopted in many sub-Saharan African
countries [1]. The concept of the time-
and population-limited use of an anti-
malarial for a specific purpose and linked
to existing routine health-care visits led to
its evaluation in settings where malaria is
highly endemic among infants, who have
limited immunity to malaria and are at
great risk of anemia and of rapid pro-
gression to severe disease and death. The
demonstration by Schellenberg et al. [2]
that IPT in infants (IPTi) with sulfadox-
ine-pyrimethamine (SP) at the time of
routine immunization visits led to sub-
stantial reductions in illness and severe
anemia was groundbreaking and rekindled
the idea of the preventive use of antima-
larials in young children. Results from an
additional trial of IPTi with amodiaquine
given at 3, 5, and 7 months of age provided
equally promising results [3]. The IPTi
Consortium, a group of experienced pub-
lic health scientists interested in under-
standing whether this approach could lead
to an additional viable malaria-prevention
strategy, was formed to identify the infor-
mation needs and appropriate methods
and studies that would clarify the value of
IPTi [4].
The study reported in this issue of the
Journal of Infectious Diseases by Macete et
al. [5] is part of the first set of results from
trials by the IPTi consortium that are cen-
tered on the safety and efficacy of IPTi
with SP. These results come just 1 year
after the promising results of the 2-year
follow-up of the initial Tanzania study [6]
and 6 months after an additional IPTi
study in Ghana [7]. Although additional
study results will be forthcoming, can we
get a sense of where this is headed?
First, if the drug is not safe, this will all
end very quickly. However, Macete et al.
provide important evidence that the drug
was well tolerated in infants and was not
associated with adverse reactions or an ad-
verse impact on laboratory measures and
blood chemistry levels. Importantly, no
adverse effects were observed on the im-
munogenicity of the Expanded Program
of Immunization (EPI) vaccines that were
administered concurrently. This is very
encouraging as we await the review of
these measures from the full set of studies,
which will be critical in this assessment of
safety.
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Table 1. Efficacy of intermittent preventive treatment in infants in Africa, from 4 completed trials.
Study parameter Schellenberg et al. [2, 6] Chandramohan et al. [7] Macete et al. [5] Massaga et al. [3]
Country Tanzania Ghana Mozambique Tanzania
Intervention drug SP SP SP AQ
Recruitment year(s) 1999–2000 2000–2002 2002–2004 1999
Entomological inoculation rate/year 29 418 38 405
Transmission Perennial Highly seasonal Perennial with
seasonal peaks
Holoendemic perennial
Incidence rate/year of clinical malaria in placebo group 0.36 1.02 0.43 2.19
Antimalarial drug resistance by day 14, % (drug)a 31 (SP) 22 (SP) 17 (SP) 3 (AQ)
Use of bed nets, placebo/intervention, % 76/79b,c 17/19c 14/15c 30/32d
Ages at dosing, months 2, 3, 9 3, 4, 9, 12 3, 4, 9 3, 5, 7e
No. of children enrolled, placebo/active 351/350 1242/1243 755/748 145/146
Protective efficacy, % (95% CI) By 12 months By 15 months By 12 months By 9 months
Clinical malaria (all episodes) 62.3 (44.2–74.6) 24.8 (14.3–34.0) 22.6 (1.6–39.2) 64.7 (42.4–77.2) (No iron)
60.7 (35.9–75.9) (Iron)
Clinical malaria with high-density infection 67.8 (48.8–79.8) 23.6 (11.1–34.3) 26.4 (5.1–42.9) 72.4 (52.5–83.9) (No iron)
68.2 (46.5–81.1) (Iron)
All-cause hospital admissions 30.0 (8.1–46.6) 12.7 (4.8 to 27.3) 19.0 (4.0–31.0) 59.9 (23.0–79.1) (No iron)
52.9 (12.4–74.7) (Iron)
All-cause severe anemia 50.3 (7.6–73.2) 35.5 (11.2–53.1)f 12.7 (17.3 to 35.1) 71.2 (38.5–87.0) (Iron)
74.4 (43.4–88.4) (No iron)
Rebound effect None: sustained effect
(10–24 months)
Yes: more high-density
parasitemia in children
16–24 months old.
None for severe
anemia.
None (10–24 months) None (9–13 months). No
extended follow-up
data available after 13
months.
NOTE. AQ, amodiaquine; CI, confidence interval; SP, sulfadoxine-pyrimethamine.
a Percentage of clinical and parasitological treatment failure by day 14 in symptomatic children !5 years old.
b Modified from Schellenberg et al. [2] by including only children with known bed-net data.
c Mostly untreated nets in the studies by Schellenberg et al. [2] and Chandramohan et al. [7]. Untreated nets only in the study by Macete et al. [5].
d Insecticide-treated nets.
e Not administered with routine vaccinations.
f Children hospitalized with severe anemia.
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What about efficacy? The growing spec-
trum of studies shows variations in effi-
cacy (table 1). Just as we should not expect
this intervention to solve all the problems
of malaria in African children, we should
not be surprised that the results will vary
in different studies and settings. Per the
IPTi Consortium plans and the standards
for reporting on randomized controlled
trials [4], Macete et al. report a predeter-
mined set of outcomes. The episodes of
malaria illness (with varying parasite den-
sity criteria), severe anemia, frequency of
outpatient visits and hospital admissions,
and other illness findings (e.g., respiratory
symptoms, diarrheal illness, splenomegaly,
and anemia during the short interval after
dosing) were all recorded. The protective
efficacy (PE) for clinical malaria with more
or less strict criteria ranged from 22.2%
to 26.4%. The PE estimate for severe ane-
mia was 17%, but this result was not sta-
tistically significant; there was a statistically
significant reduction in hospital admis-
sions for anemia during the month after
doses 1 and 2 of the antimalarial. There
were significant reductions in all-cause
hospital admissions (19%), and fewer
health-care facility visits for children with
respiratory symptoms or diarrhea were
observed, during the month after the first
or second dose. The authors refrain from
discussing these nonmalaria findings, but
similar observations for respiratory symp-
toms were made in the earlier trial by
Schellenberg et al. [2], which may be con-
sistent with efficacious use of a weak an-
tibiotic (SP) in a preventive mode. Im-
portantly, unlike the previous study in
Ghana, there was no indication of a re-
bound effect within the year after the com-
pletion of the third dose.
However, some of the findings were not
as dramatic as those of previous reports
(table 1). So is this disappointing, or does
it simply demonstrate the inherent var-
iability of malaria and its interventions?
That is, the studies differ somewhat in
transmission intensity; transmission sea-
sonality; timing of dosing of the drug
(starting at age 2 vs. 3 months); timing of
the assessment of main end points (12 vs.
9 or 15 months); parasite resistance to the
antimalarial drug; other illnesses or nu-
trient deficiencies affecting anemia; cov-
erage with other malaria prevention and
treatment interventions, such as iron sup-
plementation and the use of (insecticide-
treated) bed nets; and other features not
measured or reported. Of interest, the SP
study showing the greatest impact (in Tan-
zania) also had the highest coverage of bed
nets. Furthermore, in the Ghana trial, the
use of bed nets appeared to mitigate the
effect of rebound malaria; but, in contrast
to children without insecticide-treated nets,
no rebound effect of high-parasite-density
malaria was observed in children pro-
tected by the nets.
Nonetheless, the combined data from
the 4 trials suggest that, across different
investigations, with different transmission
intensity and seasonality settings and even
different drugs, there is substantial (albeit
variable) protective efficacy of IPTi in al-
tering the frequency of severe anemia, ma-
laria illness, and hospital admissions. The
initial enthusiasm associated with very high
efficacy may be moderated with the lower
protective efficacy seen in the more recent
trials, but the efficacy remains and is not
trivial.
Decisions about recommending the in-
troduction of IPTi will come soon—the
set of studies of the safety and efficacy of
SP are expected to be formally reviewed
this year. The efficacy and safety decisions
derived from the individual studies and
the combined analysis will offer a more
complete picture for considering policy is-
sues and next steps. The IPTi Consortium
investigators will need to confront the
evolving increase in antifolate resistance
that could eventually preclude the use of
SP. SP has a combination of features that
may make it uniquely suitable for use as
IPT: it is cheap, it has a relatively long half-
life (3 days for pyrimethamine and 7 days
for sulfadoxine), it is very well tolerated
in young infants (unlike many other drugs),
and it can be given as a single dose. The
feasibility of the IPTi approach will benefit
greatly from linkage with immunization
programs that provide a venue to achieve
high coverage with directly observed ther-
apy at a few key time points in an infant’s
life. This partnership with immunization
programs makes it likely that IPTi with SP
will be very cost-effective even if the ef-
ficacy turns out to be more modest than
was suggested in the first study. Cost-ef-
fectiveness may be somewhat less favor-
able, although still substantial, if some of
the alternative drugs are considerably more
expensive and require multiday dosing
that must be done in the home. The half-
life of the drug may also need to be taken
into consideration when estimating how
the implementation of IPTi may affect the
spread of drug-resistant parasites [8]. The
IPTi Consortium is addressing these issues
with studies of the safety, tolerability, and
efficacy of other drugs with different half-
lives and multiday regimens [4].
The sum of all this is the justification
for having an IPTi Consortium. The pub-
lic health community needs focused at-
tention on important intervention strat-
egies that are thoroughly probed by a set
of studies that address the expected vari-
ations. The malaria-research community
can benefit in many different ways from
this example of a well-coordinated con-
sortium of scientists with a comprehensive
and targeted research agenda.
We have often expected too much from
a single intervention. If IPTi is adopted, it
will need to find its place within the scaling
up of existing preventive interventions,
such as insecticide-treated bed nets or
indoor residual spraying. Currently, an-
timalarial drug use for young children in
settings where malaria is endemic focuses
on case management, which must rely on
prompt recognition of illness and rapid
action by families and health-care workers
to respond to the illness. The proactive
public health approach using IPTi builds
on existing contacts with high-risk infants
and appears to offer substantial improve-
ment in their health. We will see, but this
could be very helpful.
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